Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

doi:10.1056/NEJMoa0800251

Volume 358:2698-2703		June 19, 2008		Number 25

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

Naomi N. Hunder, M.D., Herschel Wallen, M.D., Jianhong Cao, Ph.D., Deborah W. Hendricks, B.Sc., John Z. Reilly, B.Sc., Rebecca Rodmyre, B.Sc., Achim Jungbluth, M.D., Sacha Gnjatic, Ph.D., John A. Thompson, M.D., and Cassian Yee, M.D.

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Supplementary Material

Purchase this article

Perspective
by Weiner, L. M.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

SUMMARY

We developed an in vitro method for isolating and expandingautologous CD4+ T-cell clones with specificity for the melanoma-associatedantigen NY-ESO-1. We infused these cells into a patient withrefractory metastatic melanoma who had not undergone any previousconditioning or cytokine treatment. We show that the transferredCD4+ T cells mediated a durable clinical remission and led toendogenous responses against melanoma antigens other than NY-ESO-1.

Source Information

From the Fred Hutchinson Cancer Research Center (N.N.H., H.W., J.C., D.W.H., J.Z.R., R.R., C.Y.) and the University of Washington (J.A.T., C.Y.) — both in Seattle; and the Ludwig Institute for Cancer Research (New York Branch), Memorial Sloan-Kettering Cancer Center, New York (A.J., S.G.).

Address reprint requests to Dr. Yee at the Fred Hutchinson Cancer Research Center, Room D3-100, 1100 Fairview Ave. N., Seattle, WA 98109, or at cyee{at}fhcrc.org.

Full Text of this Article

Comments and questions? Please contact us.